Imagion Biosystems is pleased to announce a pro-rata renounceable rights issue (Offer) to fund the manufacture of the nanoparticle material, the undertaking of a first-in-human study (where sufficient capital is raised), and for general working capital purposes.
Read the Pro-Rata Renounceable Rights Issue.
The Stock Network Interview – Opening US trial sites for MagSense® breast cancer imaging
October 17, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how MagSense® looks to improve upon today’s imaging, what the